Get started
Author

Farjana Jahan Fattah

Observed names: F J Fattah, F. Fattah, Farjana Fattah, Farjana J Fattah, Farjana J. Fattah, Fattah, Farjana
Observed institutions: Kansai Medical University, University of Minnesota, Salk Institute for Biological Studies, Harold C. Simmons Comprehensive Cancer Center, Case Western Reserve University, Columbia University, The University of Texas Southwestern Medical Center
ORCID: 0000-0002-7897-2788
Observed ORCID: 0000-0002-7897-2788
OpenAlex ID: A5022011884
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
2013 · Julio Morales, Longshan Li, et al. · Critical Reviews in Eukaryotic Gene Expression · 610
Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells
2010 · Farjana Fattah, Eu Han Lee, et al. · PLoS Genetics · 244
PDF
Immune dysregulation in cancer patients developing immune-related adverse events
2018 · Shaheen Khan, Saad A. Khan, et al. · British Journal of Cancer · 194
PDF
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
2016 · Xiumei Huang, Edward A. Motea, et al. · Cancer Cell · 129
PDF
Regulation of Telomere Length and Suppression of Genomic Instability in Human Somatic Cells by Ku86
2004 · Kyungjae Myung, Goutam Ghosh, et al. · Molecular and Cellular Biology · 109
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
2018 · David E. Gerber, M. Shaalan Beg, et al. · British Journal of Cancer · 103
PDF
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
2018 · Ke Gong, Gao Guo, et al. · Journal of Clinical Investigation · 98
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
2020 · Ke Gong, Gao Guo, et al. · Nature Cancer · 90
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
2015 · Z Moore, G Chakrabarti, et al. · Cell Death and Disease · 89
PDF
Ku70 , an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells
2008 · Farjana J. Fattah, Natalie F. Lichter, et al. · Proceedings of the National Academy of Sciences · 81
Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair
2014 · Julio C. Morales, Patricia Richard, et al. · Nucleic Acids Research · 50
PDF
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
2015 · David E. Gerber, David A. Boothman, et al. · Lung Cancer · 48
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
2023 · Sheena Bhalla, Farjana J. Fattah, et al. · Lung Cancer · 47
PDF
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
2021 · Murtaza Ahmed, Mitchell S von Itzstein, et al. · Journal for ImmunoTherapy of Cancer · 45
PDF
The Transcription Factor TFII-I Promotes DNA Translesion Synthesis and Genomic Stability
2014 · Farjana J. Fattah, Kodai Hara, et al. · PLoS Genetics · 44
PDF
Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers
2014 · Lifen Cao, Long Shan Li, et al. · Antioxidants and Redox Signaling · 40
Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer
2017 · Muhammad Shaalan Beg, Xiumei Huang, et al. · Journal of Surgical Oncology · 37
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
2022 · Mitchell S. von Itzstein, Amrit S. Gonugunta, et al. · Cancer Immunology Immunotherapy · 36
PDF
The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair
2016 · Praveen L. Patidar, Edward A. Motea, et al. · Nucleic Acids Research · 29
PDF
A role for XLF in DNA repair and recombination in human somatic cells
2014 · Farjana Jahan Fattah, Junghun Kweon, et al. · DNA repair · 28
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer
2020 · David E. Gerber, William C. Putnam, et al. · Clinical Cancer Research · 27
PDF
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's-Like Phenomenon
2020 · Shaheen Khan, Mitchell S. von Itzstein, et al. · The Oncologist · 26
PDF
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
2019 · Jin-Sung Chung, Vijay Ramani, et al. · Clinical Cancer Research · 26
A comparative study of the immunity region of lambdoid phages including Shiga-toxin-converting phages. Molecular basis for cross immunity.
2000 · Kazi Riaz Fattah, Satoshi Mizutani, et al. · Genes & Genetic Systems · 25
PDF
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy
2022 · Mitchell S. von Itzstein, Amrit S. Gonugunta, et al. · Cancers · 23
PDF
Works count: 114
Citation count: 2,490
H-index: 24
I10-index: 34
Year
Topic
Type